Evidence map›Paper›PMID 30937117›Full record

ArticleJournal of clinical medicine research2019

Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.

Seigo Sugiyama, Hideaki Jinnouchi, Akira Yoshida, Kunio Hieshima, Noboru Kurinami, Katsunori Jinnouchi, Motoko Tanaka, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Seigo SugiyamaDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Hideaki JinnouchiDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Akira YoshidaDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Kunio HieshimaDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Noboru KurinamiDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Katsunori JinnouchiDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Motoko TanakaDepartment of Nephrology, Akebono Clinic, Kumamoto, Japan.
Tomoko SuzukiDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Fumio MiyamotoDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Keizo KajiwaraDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Tomio JinnouchiDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Diabetes Care Center · USAkebono Clinic · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge randomized clinical trials of patients with type 2 diabetes mellitus (T2DM) and at high risk for cardiovascular disease revealed that sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduced renal events. However, the trials included small numbers of patients with moderate-to-severe chronic kidney disease (CKD). Therefore, the renoprotective effects of SGLT2 inhibitors remain unknown in T2DM patients complicated with impaired renal function. We examined if SGLT2 inhibitors conferred beneficial effects on kidney function in T2DM patients with CKD.

methodsWe retrospectively recruited T2DM patients who were newly treated with add-on of SGLT2 inhibitors and suffered from moderate-to-severe renal impairment with CKD stages 3b-4 (15 < estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m

resultsWe analyzed 42 T2DM patients with median eGFR of 40.4 mL/min/1.73 m

conclusionsThis study revealed the promising observations that add-on treatment with SGLT2 inhibitors exerted significant renoprotective effects, culminating in improvements in annual decline in eGFR and urinary protein excretion in T2DM patients with CKD stages 3b-4, but did not significantly reduce HbA1c. Further prospective clinical trials are warranted to fully elucidate the effects of SGLT2 inhibitors on glycemic control and renal function in T2DM patients with moderate-to-severe renal impairment.

Indexed as

Annual eGFR declineEstimated glomerular filtration rateKidneyRapid eGFR declinerRenoprotectionSodium-glucose co-transporter 2 inhibitorsType 2 diabetes mellitusUrine protein-to-creatinine ratio

Identifiers

PMID30937117
PMCPMC6436561
OpenAlexW2920867884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.